Neeraj Agarwal/primeinc.org
Jun 3, 2025, 08:19
Neeraj Agarwal Highlights Promising T-Cell Engager Data in Prostate Cancer at ASCO 2025
Neeraj Agarwal, Postdoctoral fellow at City of Hope, posted on X:
“Just in from ASCO25.
Finally a T-cell engager in prostate cancer mCRPC with minimal CRS syndrome (only grade 1, all outpatient dosing) and promising efficacy.
Congrats Mark Stein and team Journal of Clinical Oncology.”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 13:48
Jul 19, 2025, 13:42
Jul 19, 2025, 13:28
Jul 19, 2025, 11:05
Jul 19, 2025, 10:29
Jul 19, 2025, 10:12
Jul 19, 2025, 09:55